Table 3.
Typical gestational changes in PK parameters of semi-physiological model by trimester compared with non-pregnant
| Docetaxel | Paclitaxel | Doxorubicin | Epirubicin | |
|---|---|---|---|---|
| EGA 12 weeks | ||||
| CL (L/h) | + 15.4% | – | + 10.4% | + 5.24% |
| VMEL (μmol/h) | – | + 16.6% | – | – |
| V1 (L) | + 4.26% | + 3.82% | + 3.79% | + 3.71% |
| V2 (L) | + 4.63% | – | + 11.7% | + 3.59% |
| V3 (L) | + 15.7% | + 15.6% | – | + 15.9% |
| EGA 28 weeks | ||||
| CL (L/h) | + 24.0% | – | + 16.8% | + 11.4% |
| VMEL (μmol/h) | – | + 26.7% | – | – |
| V1 (L) | + 17.7% | + 14.9% | + 14.7% | + 14.2% |
| V2 (L) | + 20.0% | – | + 29.1% | + 13.5% |
| V3 (L) | + 38.6% | + 38.3% | – | + 39.0% |
| EGA 40 weeks | ||||
| CL (L/h) | + 20.6% | – | + 16.0% | + 15.4% |
| VMEL (μmol/h)) | – | + 24.9% | – | – |
| V1 (L) | + 30.2% | + 27.8% | + 27.6% | + 27.2% |
| V2 (L) | + 32.2% | – | + 46.3% | + 26.6% |
| V3 (L) | + 57.3% | + 56.9% | – | + 57.7% |